Patrys Reports 'Positive' Results for Deoxymabs in Autoimmune Vasculitis Treatment

Therapeutic antibody company Patrys (ASX:PAB) reported "positive' preclinical data for deoxymabs in autoimmune disease anti-neutrophil cytoplasmic antibody (ANCA) vasculitis, according to a Tuesday fi

MT NewswiresApr 10 03:14 ET

Patrys Releases Positive Data From Deoxymabs Study to Treat ANCA Vasculitis

Patrys (ASX: PAB) has released positive data from pre-clinical studies using deoxymabs PAT-DX1 and PAT-DX3 in animal models of the autoimmune disease anti-neutrophil cytoplasmic antibody (ANCA) vasculitis.

Small CapsApr 8 22:46 ET

Patrys to Present at International Conference on Use of Deoxymabs in Autoimmune Disease Treatment

Patrys Ltd (ASX:PAB) will present new data from preclinical studies assessing PAT-DX1 in animal models of anti-neutrophil cytoplasmic antibody (ANCA) vasculitis, a type of auto-immune disease, at the 21st International Vasculitis Workshop in Barcelona next month.

Investing.com Mar 3 19:55 ET

Patrys to Begin Production of PAT-DX1 in Q1 2024

Patrys (ASX:PAB) received notice from its contract manufacturing and development organization that a slot for the Good Manufacturing Practice (GMP) production of PAT-DX1 antibody will open in the firs

MT NewswiresDec 13, 2023 02:44 ET

Stocks of the Hour: Patrys, Leeuwin Metals, American West Metals

Patrys (ASX:PAB), a therapeutic antibody development company, announced that its Contract Manufacturing and Development Organisation (CDMO) has confirmed that a manufacturing slot for the GMP producti

sharecafeDec 12, 2023 19:43 ET

Patrys (ASX:PAB) Receives $3.35m R&D Tax Incentive Refund

The Market HeraldJan 29, 2023 22:41 ET